HAMP and Alzheimer disease: Previous studies have demonstrated that hepcidin is distributed around Aβ plaques [59], that hepcidin level is increased in the serum of AD patients [60,61,62], and is suggested as a potential blood biomarker for identifying risk of AD [63].